Batf3-Dependent Genes Control Tumor Rejection Induced by Dendritic Cells Independently of Cross-Presentation
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The BATF3-dependent cDC1 lineage of conventional dendritic cells (cDC) is required for rejection of immunogenic sarcomas and for rejection of progressive sarcomas during checkpoint blockade therapy. One unique function of the cDC1 lineage is the efficient cross-presentation of tumor-derived neoantigens to CD8+ T cells, but it is not clear that this is the only unique function of cDC1 required for tumor rejection. We previously showed that BATF3 functions during cDC1 lineage commitment to maintain IRF8 expression in the specified cDC1 progenitor. However, since cDC1 progenitors do not develop into mature cDC1s in Batf3−/− mice, it is still unclear whether BATF3 has additional functions in mature cDC1 cells. A transgenic Irf8-Venus reporter allele increases IRF8 protein concentration sufficiently to allow autonomous cDC1 development in spleens of Batf3−/− mice. These restored Batf3−/− cDC1s are transcriptionally similar to control wild-type cDC1s but have reduced expression of a restricted set of cDC1-specific genes. Restored Batf3−/− cDC1s are able to cross-present cell-associated antigens both in vitro and in vivo. However, Batf3−/− cDC1 exhibit altered characteristics in vivo and are unable to mediate tumor rejection. These results show that BATF3, in addition to regulating Irf8 expression to stabilize cDC1 lineage commitment, also controls expression of a small set of genes required for cDC1-mediated tumor rejection. These BATF3-regulated genes may be useful targets in immunotherapies aimed at promoting tumor rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The presence of tumor-infiltrating DCs expressing the transcription factor BATF as well as the CD103 marker has been shown to be essential for presentation of neoantigens and activation of cytotoxic T cells in the TME (197,198).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [198]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081 · cited 2×
“Batf3 / cDC1 do not mediate fibrosarcoma rejection in vivo Previously, we showed that transplanted immunogenic fibrosarcomas cannot be rejected by Batf3 / mice, but that IL12treated Batf3 / mice reacquire a population of cDC1 cells and can also mount antitumor responses (2, 15).”
BackgroundSelf-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · cited 1×
“The ability of checkpoint blockade to mediate antitumor responses against progressively growing sarcomas was shown to also require BATF3-dependent cDC1s (10-12).”
BackgroundThe Immunological Genome Project: networks of gene expression in immune cells
The Immunological Genome Project Consortium, Heng, T. S. P., Painter, M. W., Elpek, K., Lukacs-Kornek, V., Mauermann, N., Turley, S. J., Koller, D., Kim, F. S., Wagers, A. J., et al. (2008) · Nature Immunology · doi:10.1038/ni1008-1091 · Cited by 1,864 · cited 1×
“Although Itga8 expression is not limited to the immune system, its expression on cDC1s could facilitate interactions with the tumor microenvironment (25, 37).”
BackgroundBöttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857 · cited 1×
“Another study showed that NK cell release of XCL1 in tumors may recruit cDC1s into tumors, but stated that loss ofXcr1was not sufficient to block intratumor cDC1 accumulation (43).”
BackgroundCd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,328
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.012 · Cited by 1,201
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Self-citationCCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions
Ohl, L., Mohaupt, M., Czeloth, N., Hintzen, G., Kiafard, Z., Zwirner, J., Blankenstein, T., Henning, G., & Förster, R. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.014 · Cited by 1,086
Cited by
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity
Ferris, S. T., Durai, V., Wu, R., Theisen, D. J., Ward, J. P., Bern, M. D., Davidson, J. T., Bagadia, P., Liu, T., Briseño, C. G., et al. (2020) · Nature · doi:10.1038/s41586-020-2611-3 · Cited by 611
Self-citationEngineering dendritic cell vaccines to improve cancer immunotherapy
Perez, C. R., & De Palma, M. (2019) · Nature Communications · doi:10.1038/s41467-019-13368-y · Cited by 505
Genetic models of human and mouse dendritic cell development and function
Anderson, D. A., Dutertre, C.-A., Ginhoux, F., & Murphy, K. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00413-x · Cited by 313
Self-citationThe role of dendritic cells in cancer and anti-tumor immunity
Marciscano, A. E., & Anandasabapathy, N. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101481 · Cited by 298
Metadata
- Authors
- Theisen, D. J., Ferris, S. T., Briseño, C. G., Kretzer, N., Iwata, A., Murphy, K. M., & Murphy, T. L.
- Affiliations
- Washington University in St. Louis (US)
- 1Department of Pathology and Immunology, Washington University in St. Louis, School of Medicine, St. Louis, Missouri.
- ORCID
- Venue
- Cancer Immunology Research
- Published
- 2019-01-01
- Volume
- 7
- Issue
- 1
- Pages
- 29-39
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- PMC
- PMC12093468
- OpenAlex
- W2902555145
- Cited by
- 66
- References
- 45
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 7 · 2023: 10 · 2022: 5 · 2021: 9 · 2020: 11 · 2019: 8
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute (HHMI)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- Batf3, myeloid dendritic cells, tumor rejection, cross-presentation, IRF8, checkpoint blockade, cancer immunotherapy
- MeSH terms
- Interferon Regulatory Factor-8, Animals, Dendritic Cells, Female, Fibrosarcoma, Graft Rejection, Lymph Nodes, Male, Mice, Inbred C57BL, Repressor Proteins, Spleen, Mice, Knockout, Oligonucleotide Array Sequence Analysis, Cell Line, Tumor, Interferon Regulatory Factors, Basic-Leucine Zipper Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Batf3-Dependent Genes Control Tumor Rejection Induced by Dendritic Cells Independently of Cross-Presentation. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0138
- The paper
- Theisen, D. J., Ferris, S. T., Briseño, C. G., Kretzer, N., Iwata, A., Murphy, K. M., & Murphy, T. L. (2019). Batf3-Dependent Genes Control Tumor Rejection Induced by Dendritic Cells Independently of Cross-Presentation. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0138
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.